Study on the Effectiveness of Hypothermal Sulphurous Water in Wound Hygiene
Launched by UNIVERSITY OF ROMA LA SAPIENZA · Dec 4, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The effectiveness of sulphurous thermal waters in the treatment of complex or difficult wounds has been known since ancient times.
In recent years, the increase in life expectancy, the aging of the population and survival of chronically ill subjects lead to the outbreak of "hard to heal" wounds presenting multi drug resistant germs (MDR). Recent studies have shown that the effectiveness of thermal waters is not only related to the presence of dissolved ions but, as in the case of sulphurous ones, to the presence of hydrogen sulfide, a gas transmitter that diffuses freely through the skin, ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients \>18 years old
- • Any comorbidities (except very severe I, II immune deficiencies)
- • Any systemic drug therapy
- • Any associated dressing (except peroxides)
- • Acute or chronic wounds requiring wound care treatment
- • Genital/oral wounds
- • Infected wounds, including MDR pathogens
- • Biofilmed wounds
- Exclusion Criteria:
- • Unexplored fistula
- • Enteric fistula
- • Exposure of fascia, vessels, bones, organs
- • Pyoderma Gangrenosum (monotherapy)
- • Implanted or penetrating devices (CVC , Port-a-cath, drainages, peritoneal dialysis, external fixators....etc.)
- • Exposed implants(nails, plates, internal defibrillator, Pace maker)
- • Local antibiotic therapy (not supported by antibiogram)
About University Of Roma La Sapienza
The University of Roma La Sapienza, one of Italy's premier research institutions, is dedicated to advancing medical science and improving patient outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses its extensive expertise in diverse fields, including medicine, biotechnology, and public health, to conduct rigorous and ethically sound research. Committed to fostering educational excellence and promoting groundbreaking discoveries, La Sapienza actively engages in clinical trials that aim to address critical health challenges and contribute to the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bagni Di Tivoli, Rome, Italy
Patients applied
Trial Officials
Serena Crucianelli, MD
Principal Investigator
La Sapienza University of Rome
Mario Fontana, MD, PhD
Study Director
La Sapienza University of Rome
Vincenzo Romano Spica, MD, PhD
Study Chair
Foro Italico University of Rome
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported